BACKGROUND: Mammographic calcifications can be a marker of malignancy, but their association with prognosis is less well established. In the current study, the authors examined the relationship between calcifications and breast cancer prognostic factors in the population-based Carolina Mammography Registry. METHODS: The current study included 8472 invasive breast cancers diagnosed in the Carolina Mammography Registry between 1996 and 2011 for which information regarding calcifications occurring within 2 years of diagnosis was reported. Calcification-specific Breast Imaging Reporting and Data System (BI-RADS) assessments were reported prospectively by a radiologist. Tumor characteristic data were obtained from the North Carolina Central Cancer Registry and/or pathology reports. Multivariable-adjusted associations between the presence of calcifications in the breast affected by cancer and tumor characteristics were estimated using logistic regression. Statistical tests were 2-sided. RESULTS: The presence of calcifications was found to be positively associated with tumors that were high grade (vs low grade: odds ratio [OR], 1.43; 95% confidence interval [95% CI], 1.10-1.88) or had an in situ component (vs without: OR, 2.15; 95% CI, 1.81-2.55). Calcifications were found to be inversely associated with hormone receptor-negative status (vs positive status: OR, 0.73; 95% CI, 0.57-0.93), size >35 mm (vs 8 mm: OR, 0.47; 95% CI, 0.37-0.61), and lobular tumors (vs ductal: OR, 0.39; 95% CI, 0.22-0.69). The association between the presence of calcifications and an in situ component was limited to BI-RADS category 4 and 5 calcifications and was absent for BI-RADS category 2 or 3 calcifications (P for heterogeneity <.01). The association with tumor size was found to be strongest for BI-RADS categories 3 and 4 (P for heterogeneity <.01). CONCLUSIONS: Calcifications were found to be associated with both unfavorable (high grade) and favorable (small size, hormone receptor positivity) prognostic factors. Detailed analysis of the biological features of calcifications is necessary to understand the mechanisms driving these associations.
INTRODUCTION
Calcifications are calcium deposits within the breast that appear as white, opaque markings on mammograms. Currently, the major role of calcifications in breast imaging is in the diagnosis of cancer, in which they can be noted in association with invasive breast cancer and/or ductal carcinoma in situ (DCIS). 1, 2 Calcifications can appear in an array of morphologic patterns and distributions that may or may not be suspicious for cancer; positive predictive values have been published previously. [3] [4] [5] [6] [7] The American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS) provides standard terms for describing these morphologic patterns and distributions. 1 In addition, the BI-RADS lexicon defines a classification scheme with which to convey a radiologist's level of suspicion that a finding is associated with cancer. Using this semiquantitative BI-RADS scale, calcifications can be categorized using a range from benign (BI-RADS category 2) to highly suggestive of malignancy (BI-RADS category 5).
In addition to their important role in breast cancer detection, there is evidence that calcifications also may have prognostic value. Calcifications have been associated with higher-grade, [8] [9] [10] [11] [12] [13] smaller size, 9,11,14 lymph node-positive, 10 hormone receptor-negative, 12, 13, 15 and human epidermal growth factor receptor 2 (HER2)-positive [12] [13] [14] tumors. Many of these studies were conducted among women with tumors measuring <15 mm in size. [8] [9] [10] 13 Of those studies that did not select patients according to tumor size, all were single-institution patient series with <1000 subjects studied. [14] [15] [16] [17] Moreover, in some studies, the associations were reported with respect to particular calcification types, such as casting, comedo, and crushed stone morphologies, which typically correspond to BI-RADS category 4 and 5 calcifications. [8] [9] [10] [11] [12] [13] 16 Other studies 14, 15, 17 did not distinguish between calcification types. Thus, it is unclear how associations with prognosis differ for benign-appearing versus suspicious calcifications.
We sought to determine the relationship between mammographic calcifications and breast cancer prognostic factors in a large, population-based breast imaging registry in which tumors were unselected for size, with the rationale that a greater understanding of the relationship between calcifications and prognostic factors may provide a more complete understanding of long-term prognosis and may inform treatment approaches. We examined: 1) associations between the presence of any calcifications and breast cancer prognostic factors; and 2) associations between specific BI-RADS classifications of calcifications and prognostic factors. We hypothesized that BI-RADS category 4 (suspicious) and category 5 (highly suggestive of malignancy) calcifications would be more strongly associated with poor prognostic factors compared with BI-RADS category 2 (benign) or category 3 (probably benign) calcifications.
MATERIALS AND METHODS
The current study used data from the Carolina Mammography Registry (CMR), which has been described previously. 18 Briefly, the CMR is a population-based breast imaging registry that operates in partnership with imaging facilities across North Carolina. Health, lifestyle, and imaging information is collected prospectively through the administration of patient and radiologist questionnaires. Cancer outcomes are determined through linkage with the North Carolina Central Cancer Registry (NCCCR) and pathology reports obtained from the University of North Carolina Lineberger Comprehensive Cancer Center rapid case ascertainment program and CMR facilities. The current study was approved by the UNC-Chapel Hill Institutional Review Board.
Population
The current analysis included female CMR participants diagnosed with unilateral, invasive breast cancer between 1996 and 2011 ( Fig. 1 ). Women diagnosed with in situ disease only were excluded. Inclusion required at least 1 screening or diagnostic mammogram of the affected breast performed within 2 years of diagnosis and with data regarding the presence of calcifications. Women who were treated with tamoxifen or raloxifene or who reported a history of breast augmentation or reduction were excluded. A total of 12,480 mammograms performed among 8472 cases of breast cancer were identified.
Mammographic Data
Mammographic information was collected prospectively. Participants were asked the reason for the mammogram (routine screening or symptoms), screening history, and prior history of breast cancer. The radiologist recorded the mammogram indication, examination findings, BI-RADS assessments, and recommendation for follow-up.
For each mammogram, the interpreting radiologist categorized the appearance of calcifications using BI-RADS criteria. 19 BI-RADS categories were assigned separately for each breast if the mammogram was bilateral. The calcification-specific BI-RADS category was a separate assessment from the BI-RADS category assigned for the overall examination. If there were multiple mammograms of the breast affected by cancer within the 2 years preceding diagnosis, calcification information for use in the current analysis was obtained from the mammogram closest in time to diagnosis. The median time between the mammogram selected for study and breast cancer diagnosis was 14 days (interquartile range, 5-31 days). For the purposes of the current study, examinations with calcification-specific BI-RADS categories of 2, 3, 4, or 5 were considered positive for the presence of calcifications and examinations with calcifications-specific BI-RADS categories 0 (incomplete) or 1 (negative) were considered negative. We did not have information regarding the location of calcifications relative to the tumor beyond breast laterality.
Pathologic Data
Tumor characteristics were obtained from the NCCCR or abstracted from pathology reports. Stage of disease at the time of diagnosis was coded according to Surveillance, Epidemiology, and End Results summary stage rules. 20 Estrogen receptor (ER) and progesterone receptor (PR) positivity and tumor grade were reported according to the standards of the diagnosing institution. Tumor size (in mm) was the total size of the invasive tumor, and was categorized into quintiles. Histology was classified according to the International Classification of Diseases for Oncology, 3rd Edition. 21 Histologic types present at <1% were 22 for data obtained from the NCCCR, or the reporting of any type of in situ lesion for data abstracted from pathology reports. We were unable to distinguish DCIS from lobular carcinoma in situ (LCIS) for 1140 cases due to the fact that Collaborative Stage SiteSpecific Factor 6 does not distinguish the histologic type of the in situ component for invasive cancers. Therefore, the in situ component variable was coded as "yes" if any in situ component was reported.
Covariates
Age, menopausal status, race, history of a previous mammogram, first-degree family history of breast cancer, history of a previous breast biopsy, and current hormone use were self-reported at the time of the mammogram. Women were classified as postmenopausal if they reported that their periods had stopped for any reason. Current hormone use was based on reported use of menopausal hormone therapy or hormonal contraceptives. Mammogram type (digital vs film screen) and BI-RADS mammographic density 19 were reported by the radiologist. Tumors were categorized as "screen-detected" if there was a positive screening mammogram within 12 months of diagnosis, "interval-detected" if there was a negative screening mammogram within 12 months of diagnosis, and "other" if there was no screening mammogram within 12 months of diagnosis, based on criteria used by the Breast Cancer Surveillance Consortium. 23 
Statistical Analysis
Variables were categorized as shown in Table 1 and Supporting Information Table S1 , unless otherwise specified. Differences in patient characteristics according to the presence of calcifications were evaluated using the chisquare or the Mann-Whitney U test. The relationship between the presence of calcifications in the affected breast and tumor characteristics was evaluated by estimating odds ratios (ORs) and 95% confidence intervals (95% CIs) using unconditional binary logistic regression. Initially, each tumor characteristic was examined in a univariable model. A multivariable-adjusted model was developed by including all tumor characteristics and sequentially eliminating variables with P values >.05 using backward selection (multivariable model 1). To determine the potential confounding effects of patient characteristics on the association between calcifications and tumor characteristics, we estimated a second multivariable model that in addition adjusted for patient characteristics (see Supporting Information Table S1 ) associated with the presence of calcifications (multivariable model 2). Observations with missing data were excluded from the models. Family history of breast cancer was not routinely collected before 2001, and therefore analyses using this variable were restricted to cases from 2001 or later.
We explored whether the association between the presence of calcifications in the affected breast and tumor characteristics was modified by tumor size (<15 mm vs 15 mm), mammogram type, or the presence of an in situ component in stratified analyses. Statistical Original Article differences were evaluated by comparing models with and without a cross-product interaction term using the likelihood ratio test. In addition, we estimated associations for calcification-specific BI-RADS categories using multinomial logistic regression to determine whether tumor characteristics were associated with the calcifications' perceived suspicion of malignancy.
In sensitivity analyses, we excluded cases in which women had a history of breast biopsy (2755 cases) and in which the calcification assessment was BI-RADS category 0 (81 cases), because this indicates that further imaging was needed. We also evaluated associations excluding cases that were not screen detected (4360 cases) or in which women were aged <40 years or aged > 75 years (1816 cases) to determine whether the results were influenced by screening.
Statistical analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC). All statistical tests were 2-sided. P values .05 were considered to be statistically significant.
RESULTS

Any Calcifications in the Affected Breast
Calcifications in the affected breast were reported for 1288 of the 8472 study subjects (15%). Women with calcifications were slightly younger than women without calcifications (median age of women with calcifications of 60 years vs 61 years for women without calcifications; P<.01), and were more likely to have a prior mammogram, a family history of breast cancer, a previous breast biopsy, heterogeneously dense or extremely dense breasts, and to not use hormones (see Supporting Information Table S1).
The presence of calcifications was found to be positively associated with an earlier stage of disease at the time of diagnosis, lymph node negativity, hormone receptor positivity, smaller tumor size, tubular histology, and the presence of an in situ component in univariable analyses (Table 1 ). The presence of calcifications was found to be inversely associated with lobular and mucinous histologies. In multivariable models, hormone receptor status, tumor grade, tumor size, histology, and the presence of an in situ component remained statistically significantly associated with calcifications (Table 1) . Further adjustment for patient characteristics did not appear to change the associations between calcifications and tumor characteristics, with the exception of attenuation of the association between calcifications and tubular breast cancer (Table 1) . Therefore, patient characteristics were not included in remaining analyses due to the overall lack of impact on tumor characteristic associations.
Associations between calcifications and prognostic factors were found to be similar for tumors measuring <15 mm and 15 mm in size, with the following exceptions: 1) calcifications were positively associated with intermediate tumor grade among tumors measuring 15 mm but not < 15 mm; and 2) calcifications demonstrated an inverse association with mixed ductal-lobular histology among tumors measuring <15 mm but a positive association among tumors measuring 15 mm (Fig. 2) . However, differences in associations comparing tumors measuring <15 mm and those measuring 15 mm were not found to be statistically significant for any factors examined, including grade and histology (P for interaction >.05). Associations also were similar when stratified by film screen or digital mammography and by the presence of an in situ component (P for interaction >.05) (see Supporting Information Tables S2 and  S3 ). When we excluded non-screen-detected cancers, the association between calcifications and ER negative (-)/PR positive (1) tumors (vs ER1/PR 1 tumors) was strengthened, whereas the inverse association with mucinous tumors was attenuated (see Supporting Information Table  S4 ). Associations were unaffected by excluding cases in which women reported a previous biopsy, were aged <40 years or aged > 75 years, or in which calcifications were classified as BI-RADS category 0 (see Supporting Information Table S4 ).
Calcification BI-RADS
There were some differences in association according to calcification-specific BI-RADS categories for tumor grade, size, and the presence of an in situ component (Table 2). BI-RADS category 4 and 5 calcifications were found to be strongly associated with the presence of an in situ component, whereas there was no association noted for BI-RADS category 2 or 3 calcifications (P for heterogeneity <.01). Other associations did not follow a clear pattern. For example, there was a >2-fold association between the presence of BI-RADS category 2, 3, and 5 calcifications and intermediate or high tumor grade (vs low grade), but the association between BI-RADS category 4 and intermediate or high grade was closer to the null. The inverse association between calcifications and larger tumor size observed in the overall analysis was only observed for BI-RADS category 3 and 4 calcifications ( Table 2) . Comparisons according to histology could not be made across BI-RADS groups due to the low prevalence of nonductal histologies.
DISCUSSION
In the current study, we examined the relationship between mammographic calcifications and prognostic factors among women diagnosed with invasive breast cancer. Prior studies have reported associations between calcifications and poor prognostic features as well as poorer survival. [8] [9] [10] [11] [12] [13] 15, 17, 24 We conducted the current study to determine whether those findings are generalizable to a population-based setting in which patients are unselected for tumor size or calcification type. We found that tumors diagnosed among women with mammographic calcifications were more likely to have both favorable (hormone receptor positivity, small size) and unfavorable (high grade) prognostic features. Associations varied when cases were examined according to the calcification-specific BI-RADS category, particularly with respect to tumor size, tumor grade, and the presence of an in situ component. Together, these data suggest that the presence of calcifications is associated with breast cancer prognostic factors in the general patient population and that the link with some factors depends on the type of calcification.
The findings of the current study are in agreement with previous studies reporting that calcifications are associated with the presence of carcinoma in situ, [14] [15] [16] smaller tumor size, 9,11,14 and higher tumor grade. [8] [9] [10] [11] [12] [13] However, the results herein differed from previously reported associations between calcifications and hormone receptor negativity 12, 13, 15 and lymph node positivity. 10 Several prior studies of calcifications and prognostic factors were conducted among women with tumors measuring 15 mm in size, [8] [9] [10] 13 raising questions regarding the consistency of previously reported associations among women with larger tumors. We did not find strong evidence of differences in association for tumors that measured <15 mm versus those measuring 15 mm, which suggests that previous findings among women with smaller tumors are likely applicable to women with larger tumors.
We hypothesized that the association between the presence of calcifications and prognostic factors would be strongest for calcifications that were suspicious or highly suggestive of malignancy (BI-RADS categories 4 and 5). In this population, the association between the presence of calcifications and an in situ component was consistent with our hypothesis, but associations with hormone receptor status, tumor size, and grade were not. This raises questions as to what biological mechanisms may be associated with the relationship between calcifications and prognostic factors. There are multiple potential causes of calcifications, including the development of scar tissue after a biopsy or surgery, fluid accumulation, epithelial proliferation, tissue necrosis, and inflammation. 1 Inflammation has been linked previously with poor prognosis in patients with breast cancer and disease progression, possibly due to the recruitment of macrophages that promote tumor growth and proteinases that degrade the extracellular matrix. 25 The current study finding of an association between calcifications and ER positivity is consistent with an inflammation hypothesis, because a greater number of ER-positive tumors could result from the induction of aromatase by insulin, tumor necrosis factor a, interleukin 6, and prostaglandin E2 under chronic inflammation. 26 Evaluation of tissue-based markers of inflammation among women with and without calcifications is needed to determine whether inflammation is an important link between calcifications and prognosis.
The association between BI-RADS category 4 and 5 calcifications and the presence of an in situ component in addition to the invasive tumor was one of the strongest associations observed in the current study. This was expected, given that approximately 95% of DCIS cases are detected due to mammographic abnormalities, of which calcifications are the most common (76%). 27 Calcifications are less commonly associated with LCIS, but do occur. 28, 29 To the best of our knowledge, the link between this finding and breast cancer prognosis is unclear. Although some studies have suggested that the presence of .04
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In situ component Abbreviations: BI-RADS, breast imaging-reporting and data system; CI, confidence interval; ER, estrogen receptor; OR, odds ratio; PR, progesterone receptor.
a Adjusted for all other factors shown in Table. b
Wald P-value testing the null hypothesis that effect estimates for BI-RADS 2, 3, 4, and 5 calcifications are equal. DCIS or LCIS with an invasive tumor either has no effect on disease recurrence or is a predictor of good prognosis, [30] [31] [32] [33] other studies have suggested recurrence-free survival may be lower if there is extensive DCIS within surrounding normal tissue or the DCIS is of high grade. 34, 35 We were unable to evaluate the grade of the in situ component or in situ extent in the current study. Data addressing the impact of these factors are needed to clarify the contributions of calcifications with in situ components to the prognosis of women with invasive breast cancer. Women with only in situ disease (no invasion) were excluded from the current study. The impact of calcifications on prognostic factors in patients with in situ disease without invasive cancer may differ from the findings reported herein.
The current study was limited by missing data for some tumor characteristics, particularly ER status and grade. Data missingness decreased over the course of the study period due to structural patterns in how data was reported to the NCCCR over time. Any bias related to missing data is most likely to be nondifferential and would lead to bias of associations toward the null. Thus, we believe that the results reported in the current study are unlikely to be false-positive associations due to data missingness. In addition, we did not have information regarding the location of the calcifications within the affected breast relative to the invasive tumor. Other limitations were related specifically to the analysis of calcification BI-RADS categories. Both the fact that the assignment of BI-RADS categories can vary among radiologists and the publication of new editions of the BI-RADS Atlas in 1998 and 2003 may have contributed to variability in the way that calcification-specific BI-RADS categories were assigned over the study period. A post hoc analysis of the data from the current study suggests that variability over time was likely low, with slightly more calcifications reported as BI-RADS category 4 and fewer reported as BI-RADS category 3 in 2003 or later when compared with 1998 or earlier. A single-institution study evaluating interobserver reproducibility of the BI-RADS lexicon reported nearly perfect agreement for the presence of calcifications but only fair agreement for the descriptive classification. 36 As such, validation of these results in an environment in which all films are assessed by a group of uniformly instructed radiologists is necessary to rule out the possibility that the BI-RADS-specific results were affected by differences among radiologists.
The strengths of the current study are the large population size, prospective assessment of calcifications, and detailed assessment of calcifications at the BI-RADS level.
To our knowledge, the current study is the largest to date to examine the association between mammographic calcifications and tumor characteristics, and 1 of only 2 studies regarding this subject conducted in the United States. US-based results may differ from those of previous studies conducted in Europe due to differences in recommended screening intervals. Furthermore, the CMR is populationbased, thereby increasing the likelihood that the results of the current study will be generalizable to the general population of patients with breast cancer in the United States. Administration of a patient questionnaire allowed us to rule out the possibility of confounding by patient characteristics.
The results of the current study demonstrated that the presence of mammographic calcifications in the same breast in which invasive cancer was diagnosed was positively associated with a higher tumor grade and the presence of an in situ tumor component, and inversely associated with hormone receptor negativity, larger tumor size, and lobular histology. Some associations varied according to the BI-RADs calcification category, suggesting that qualitative evaluation of calcifications may be a useful adjunct to understanding prognosis at the time of diagnosis. As more is learned regarding the consistency of the relationship between calcification types and prognosis, it is possible that the presence of calcifications could be considered alongside other major prognostic factors to help determine breast cancer treatment. In addition, greater knowledge of the biological mechanisms underlying relationships between the presence of calcifications and prognosis may identify new treatment targets, such as inflammation (discussed above). Both these hypotheses for the added value of detecting and characterizing calcifications in patients with invasive breast cancer are currently unproven and require additional evidence. We hope that the current study provides motivation for continued research along these lines.
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